Latvija - latvių - Zāļu valsts aģentūra

sopharma ad, bulgaria - desloratadīns - apvalkotā tablete - 5 mg

Latvija - latvių - Zāļu valsts aģentūra

pharma nord aps, denmark - glikozamīns - kapsula, cietā - 400 mg

Latvija - latvių - Zāļu valsts aģentūra

patent pharma kft., hungary - holekalciferols - apvalkotā tablete - 30000 sv

Europos Sąjunga - latvių - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrela hidrohlorīds - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiskie līdzekļi - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Latvija - latvių - Zāļu valsts aģentūra

g.l. pharma gmbh, austria - metadona hidrohlorīds - koncentrāts iekšķīgi lietojama šķīduma pagatavošanai - 10 mg/ml

Latvija - latvių - Zāļu valsts aģentūra

zaklady farmaceutyczne polpharma s.a., poland - klotrimazols - uz ādas lietojams šķīdums - 10 mg/ml

Europos Sąjunga - latvių - EMA (European Medicines Agency)

baxalta innovations gmbh - susoctocog alfa - a hemofīlija - antihemorāģija - asiņošanas epizožu ārstēšana pacientiem ar iegūto hemofiliju, ko izraisa antivielas pret viii faktoru. obizur ir indicēts pieaugušajiem.

Europos Sąjunga - latvių - EMA (European Medicines Agency)

novo nordisk a/s - turoctocog alfa pegol - a hemofīlija - antihemorāģija - Ārstēšanas un profilakses asiņošanas pacientiem, 12 gadi un iepriekš ar hemofilijas (iedzimtas viii faktora deficīts).

Europos Sąjunga - latvių - EMA (European Medicines Agency)

teva b.v. - telmisartāns - hipertensija - agents, kas iedarbojas uz renīna-angiotenzīna sistēmu - esenciālas hipertensijas ārstēšana pieaugušajiem.

Europos Sąjunga - latvių - EMA (European Medicines Agency)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hipofīzes un hipotalāma hormoni un analogi - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.